Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patientâ€™s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-06	US$0.3300	+8.20%	3,181

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 09:54:25 2026-07-06 EDT			5-day change	1st Jan Change
0.3300 ^USD	+8.20%		+17.86%	-51.48%

05-08	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-30	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.09M 952K 877K 814K 1.55M 104M 1.57M 10.5M 4.09M 50.91M 4.08M 3.99M 177M	P/E 2024	-0.22x	P/E 2025	-0.73x
Enterprise Value	-1.77M -1.55M -1.43M -1.32M -2.51M -169M -2.55M -17.07M -6.64M -82.77M -6.64M -6.49M -287M	EV / Sales 2024	-	EV / Sales 2025	-491,128x
Free-Float	86.49%	Yield 2024 *	-	Yield 2025	-

05-08	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-30	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-29	Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-23	Avenue Therapeutics, Inc. Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	CI
11-13	Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-11	Axsome Therapeutics, Inc. completed the acquisition of Baergic Bio, Inc. from Avenue Therapeutics, Inc..	CI
11-06	Axsome Therapeutics acquires AZD7325, a selective GABA-A modulator for treatment of epilepsy	RE
11-05	Axsome Therapeutics, Inc. entered into stock purchase agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $83.3 million.	CI
25-08-14	Avenue Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-15	Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-30	Avenue Therapeutics, Inc. and Annji Pharmaceutical Co., Ltd. Enters into A License Termination	CI
25-03-31	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-30	Avenue Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

02-23	Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease	AQ
11-06	Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics	AQ
24-11-14	Avenue Therapeutics : Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights Form 8 K	PU
24-11-14	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights	AQ
24-10-09	Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit	AQ

Avenue Therapeutics, Inc. Stock

Stocks

ATXI

US05360L4032

Biotechnology & Medical Research

Valuation: Avenue Therapeutics, Inc.

Chart: Avenue Therapeutics, Inc.

Latest news : Avenue Therapeutics, Inc.

Analysts' recommendations: Avenue Therapeutics, Inc.

Press Releases: Avenue Therapeutics, Inc.

News in other languages: Avenue Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Avenue Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

23-04-18	MÄRKTE USA/Anleger bleiben in Deckung und warten Quartalszahlen ab
23-04-18	MÄRKTE USA/Anleger mit Blick auf Berichtssaison zurückhaltend
23-04-18	MÄRKTE USA/Uneinheitlich - Goldman Sachs bremst Dow
23-04-18	MÄRKTE USA/Wall Street dürfte Schwung des späten Vortageshandels halten
23-03-09	Wall Street hard onderuit in aanloop naar banencijfer

1 day	+8.20%
1 week	+17.86%
Current month	+17.86%
1 month	-6.38%
3 months	-5.71%
6 months	-46.77%
Current year	-51.48%

1 week	0.25	0.33
1 month	0.25	0.36
Current year	0.15	0.79
1 year	0.15	0.97
3 years	0.15	93.75
5 years	0.15	2,832.76
10 years	0.15	13,882.3

Manager	Title	Age	Since
Alexandra MacLean CEO	Chief Executive Officer	59	2022-07-31
David Jin CEO	Chief Executive Officer	36	2022-03-30
Jaclyn Jaffe IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Lindsay Rosenwald CHM	Chairman	71	2015-02-08
Neil Herskowitz BRD	Director/Board Member	69	2015-07-31
Jay Kranzler CHM	Chairman	68	2023-03-06

Date	Insider	Type	Main position	Quantity	% Market Cap.
01-01	FORTRESS BIOTECH, INC.	Free	Company	111,209	3.4934%
25-03-30	FORTRESS BIOTECH, INC.	Free	Company	33,724	1.6419%
24-12-30	FORTRESS BIOTECH, INC.	Other	Company	294,800	15.4214%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AVENUE THERAPEUTICS, INC.	+8.20%	+17.86%	-2.91%	-99.61%	1.09M
ARGENX SE	-0.10%	+0.10%	+74.33%	+133.26%	57.73B
WUXI APPTEC CO., LTD.	-3.80%	-6.24%	+67.04%	+86.36%	54.69B
BIONTECH SE	+0.09%	+1.02%	-14.58%	-12.03%	23.75B
INSMED INCORPORATED	+1.17%	+5.76%	+16.31%	+467.80%	24.18B
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	+4.25%	+40.38%	-3.72%	19.82B
GENMAB A/S	+3.78%	+5.65%	+44.99%	-26.23%	17.14B
PHARMAESSENTIA CORPORATION	+3.46%	+17.72%	+206.66%	+364.07%	16.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.81%	+18.00%	+41.99%	-	15.57B
EXELIXIS, INC.	+3.04%	+5.09%	+29.48%	+196.12%	13.96B
Average	+1.14%	+5.00%	+50.37%	+122.89%	24.36B
Weighted average by Cap.	-0.41%	+3.34%	+57.90%	+139.26%

	2024	2025
Net sales	-	1.4 1.23 1.13 1.05 2 133.92 2.02 13.56 5.28 65.74 5.27 5.16 227.92
Net income	-11.65M -10.2M -9.4M -8.72M -16.57M -1.11B -16.79M -113M -43.79M -546M -43.76M -42.8M -1.89B	-2.91M -2.55M -2.35M -2.18M -4.14M -277M -4.19M -28.09M -10.93M -136M -10.92M -10.68M -472M
Net Debt	-2.59M -2.27M -2.09M -1.94M -3.69M -247M -3.74M -25.05M -9.75M -121M -9.74M -9.53M -421M	-2.86M -2.5M -2.3M -2.14M -4.06M -272M -4.11M -27.57M -10.73M -134M -10.72M -10.49M -463M